StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PCGH.L$407.00-1.09%
Fair $407.00+0.0%

PCGH.L

Polar Capital Glb Healthcare Ord

Unknown / UnknownLSE

$407.00

-4.50 (-1.09%)

Fairly Valued+0.0%Fair Value $407.00Fund rank 25/100 · Data gapFallback financials|
SA 31/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $10.8M · quality 44.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 10/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

31/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -6.3%, below the 5% threshold
Thesis & Journal · PCGH.LLocal privado en este navegador · Polar Capital Glb Healthcare Ord
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$408M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-6.3%

↓

Gross Margin

N/A

•

Debt/Equity

0.00

↓
52-Week Range$407
$319$439

TradingView lightweight chart

PCGH.L price, volumen y niveles de valoración

Último $407.00Periodo +302.0%
Fair value: $407.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

-40.5%

FCF / Net income

-0.38x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $-26.7M · net income $-28.1M · FCF $10.8M

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

105.2%+14.8% pts

FCF margin

-40.5%-24.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$-26.7M$-26.7M$65.5M$20.1M$23.8M
Net Income$-28.1M$-28.1M$62.8M$16.9M$21.5M
EPS——0.520.140.18
Net Margin105.2%105.2%95.9%84.2%90.4%
Balance Sheet
Debt/Equity0.000.000.000.10—
Cash Flow
Free Cash Flow$10.8M$10.8M$49.0M$-2.3M$-3.7M
Returns
ROE-6.3%-6.3%13.1%4.0%5.3%
Valuation
P/E——728.912261.311788.73
P/B110.14110.1495.5691.1395.11
Growth & Yield
Revenue Growth-140.7%-140.7%226.6%-15.8%—
EPS Growth——271.8%-21.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +25.2%

Total return

+25.2%

Start / end P/E

n/dx → n/dx

EPS bridge

0.52 → n/d

Residual

+25.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+25.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.